A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer

Cancer Immunology, Immunotherapy

Volumn 59, Issue 2, 2010, Pages 293-301

  Vlad, Anda M ^a,b   Budiu, Raluca A ^a,b   Lenzner, Diana E ^c   Wang, Yun ^c   Thaller, Julia A ^b   Colonello, Kelly ^d   Crowley Nowick, Peggy A ^d   Kelley, Joseph L ^d   Price, Fredric V ^d   Edwards, Robert P ^a,b,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Interleukin 2; Intraperitoneal therapy; Ovarian cancer

Indexed keywords

CD3 ANTIGEN; EOTAXIN; GAMMA INTERFERON; PLATINUM; RECOMBINANT INTERLEUKIN 2;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; BLOOD; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CATHETER INFECTION; CATHETER OCCLUSION; CD8+ T LYMPHOCYTE; CELL COUNT; CELL SECRETION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DRUG TOLERABILITY; EAR NOSE THROAT DISEASE; EOSINOPHIL; EYE EAR; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFLUENZA; INJECTION SITE PAIN; ISCHEMIA; LUNG DISEASE; LYMPHOCYTE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EOSINOPHILIA; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-2; LYMPHOCYTES; LYMPHOCYTOSIS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 71849090003     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0750-3     Document Type: Article

References (48)

1. A Jemal T Murray E Ward A Samuels RC Tiwari A Ghafoor EJ Feuer MJ Thun 2005 Cancer statistics, 2005 CA Cancer J Clin 55 10 30 10.3322/canjclin.55.1.10 15661684
2. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 10.3322/canjclin.55.2.74 15761078
3. SA Cannistra 2004 Cancer of the ovary N Engl J Med 351 2519 2529 10.1056/NEJMra041842 1:CAS:528:DC%2BD2cXhtVGksbbM 15590954 (Pubitemid 39603165)
4. AN Gordon JT Fleagle D Guthrie DE Parkin ME Gore AJ Lacave 2001 Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 3312 3322 1:CAS:528:DC%2BD3MXlvVamsr8%3D 11454878
5. DS Alberts PY Liu EV Hannigan R O'Toole SD Williams JA Young EW Franklin DL Clarke-Pearson VK Malviya B DuBeshter 1996 Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 335 1950 1955 10.1056/NEJM199612263352603 1:CAS:528:DyaK2sXivVajtA%3D%3D 8960474 (Pubitemid 26428219)
6. M Markman JA Blessing D Moore H Ball SS Lentz 1998 Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial Gynecol Oncol 69 226 229 10.1006/gyno.1998.5016 1:CAS:528:DyaK1cXksV2qs70%3D 9648592 (Pubitemid 28289964)
7. DK Armstrong B Bundy L Wenzel HQ Huang R Baergen S Lele LJ Copeland JL Walker RA Burger 2006 Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 34 43 10.1056/NEJMoa052985 1:CAS:528:DC%2BD28XhvV2qsQ%3D%3D 16394300 (Pubitemid 43048949)
8. SA Rosenberg MT Lotze LM Muul S Leitman AE Chang SE Ettinghausen YL Matory JM Skibber E Shiloni JT Vetto, et al. 1985 Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer N Engl J Med 313 1485 1492 1:STN:280:DyaL28%2FktVehug%3D%3D 3903508
9. L Elias WC Hunt 2001 A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy Oncology 61 91 101 10.1159/000055359 1:CAS:528:DC%2BD3MXntFKjt7k%3D 11528247 (Pubitemid 32786202)
10. C Grande JL Firvida V Navas J Casal 2006 Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma Anticancer Drugs 17 1 12 10.1097/01.cad.0000182748.47353.51 1:CAS:528:DC%2BD2MXht1Glt7%2FO 16317284
11. RP Edwards W Gooding BC Lembersky K Colonello R Hammond C Paradise CD Kowal AJ Kunschner M Baldisseri JM Kirkwood RB Herberman 1997 Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion J Clin Oncol 15 3399 3407 1:CAS:528:DyaK2sXnsVensbo%3D 9363872
12. M Markman B Reichman T Hakes JL Lewis Jr W Jones S Rubin R Barakat J Curtin L Almadrones W Hoskins 1992 Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer J Clin Oncol 10 1479 1484 1:STN:280:DyaK38zovV2lug%3D%3D 1517791
13. MB Atkins MT Lotze JP Dutcher RI Fisher G Weiss K Margolin J Abrams M Sznol D Parkinson M Hawkins C Paradise L Kunkel SA Rosenberg 1999 High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 2105 2116 1:CAS:528:DyaK1MXkvVSmur4%3D 10561265
14. G Fyfe RI Fisher SA Rosenberg M Sznol DR Parkinson AC Louie 1995 Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 688 696 1:STN:280:DyaK2M7ptVGiuw%3D%3D 7884429
15. F Donskov KM Bennedsgaard H Von Der Maase N Marcussen R Fisker JJ Jensen P Naredi M Hokland 2002 Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival Br J Cancer 87 194 201 10.1038/sj.bjc.6600437 1:CAS:528:DC%2BD38XltFeks7c%3D 12107842 (Pubitemid 34886343)
16. L Fumagalli P Lissoni G Di Felice S Meregalli G Valsuani S Mengo F Rovelli 1999 Pretreatment serum markers and lymphocyte response to interleukin-2 therapy Br J Cancer 80 407 411 10.1038/sj.bjc.6690371 1:CAS:528: DyaK1MXjtFyksrw%3D 10408846
17. IG Jeong KS Han JY Joung WS Choi SS Hwang SO Yang HK Seo J Chung KH Lee 2007 Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival J Korean Med Sci 22 S122 S128 10.3346/jkms.2007.22.S.S122 1:CAS:528:DC%2BD2sXhsVektrfE 17923738
18. M Markman BN Bundy DS Alberts JM Fowler DL Clark-Pearson LF Carson S Wadler J Sickel 2001 Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 1001 1007 1:CAS:528:DC%2BD3MXhvFersbg%3D 11181662
19. V Bordin L Giani S Meregalli R Bukovec MM Vaghi M Mandala F Paolorossi A Ardizzoia G Tancini S Barni F Frigerio L Fumagalli A Bordoni G Valsuani G Di Felice P Lissoni 2000 Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients Urol Int 64 3 8 10.1159/000030473 1:CAS:528:DC%2BD3cXkslyhsLw%3D 10782024
20. P Lissoni S Barni A Ardizzoia S Crispino F Paolorossi M Andres E Scardino G Tancini 1994 Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma Oncology 51 59 62 10.1159/000227311 1:STN:280:DyaK2c%2FovFSqsw%3D%3D 8265104
21. PA Palmer J Atzpodien T Philip S Negrier H Kirchner H Von der Maase P Geertsen P Evers E Loriaux R Oskam, et al. 1993 A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma Cancer Biother 8 123 136 1:STN:280: DyaK2M7gt1Ogug%3D%3D 7804353
22. A von Rohr AK Ghosh N Thatcher PL Stern 1993 Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy Br J Cancer 67 163 171
23. P Wersall H Mellstedt 1995 Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN Med Oncol 12 69 77 10.1007/BF01676706 1:STN:280: DyaK287it12jtg%3D%3D 8535664
24. L Degrate C Nobili C Franciosi R Caprotti F Brivio F Romano BE Leone R Trezzi F Uggeri 2009 Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients Langenbecks Arch Surg 394 115 121 10.1007/s00423-008-0393-4 18670745
25. TH Rand DS Silberstein H Kornfeld PF Weller 1991 Human eosinophils express functional interleukin 2 receptors J Clin Invest 88 825 832 10.1172/JCI115383 1:CAS:528:DyaK3MXlsFKrsrs%3D 1885772
26. B Lamkhioued PM Renzi S Abi-Younes EA Garcia-Zepada Z Allakhverdi O Ghaffar MD Rothenberg AD Luster Q Hamid 1997 Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation J Immunol 159 4593 4601 1:CAS:528:DyaK2sXmvVylu7w%3D 9379061
27. S Mattoli MA Stacey G Sun A Bellini M Marini 1997 Eotaxin expression and eosinophilic inflammation in asthma Biochem Biophys Res Commun 236 299 301 10.1006/bbrc.1997.6958 1:CAS:528:DyaK2sXkvVWgurc%3D 9240429 (Pubitemid 27373288)
28. S Ying DS Robinson Q Meng J Rottman R Kennedy DJ Ringler CR Mackay BL Daugherty MS Springer SR Durham TJ Williams AB Kay 1997 Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells Eur J Immunol 27 3507 3516 10.1002/eji.1830271252 1:CAS:528:DyaK1cXisF2rsw%3D%3D 9464841 (Pubitemid 28018050)
29. MJ Fernandez-Acenero M Galindo-Gallego J Sanz A Aljama 2000 Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma Cancer 88 1544 1548 10.1002/(SICI)1097-0142(20000401)88:7<1544::AID- CNCR7>3.0.CO;2-S 1:STN:280:DC%2BD3c3gsVWqtw%3D%3D 10738211 (Pubitemid 30183138)
30. L Rivoltini V Viggiano S Spinazze A Santoro MP Colombo K Takatsu G Parmiani 1993 In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 Int J Cancer 54 8 15 10.1002/ijc.2910540103 1:STN:280:DyaK3s3jvFertA%3D%3D 8386711
31. M Samoszuk 1997 Eosinophils and human cancer Histol Histopathol 12 807 812 1:CAS:528:DyaK2sXls1Wltro%3D 9225164
32. SE Leighton JG Teo SF Leung AY Cheung JC Lee CA van Hasselt 1996 Prevalence and prognostic significance of tumor-associated tissue eosinophilia in nasopharyngeal carcinoma Cancer 77 436 440 10.1002/(SICI)1097-0142(19960201) 77:3<436::AID-CNCR3>3.0.CO;2-I 1:STN:280:DyaK283ivF2qtQ%3D%3D 8630949 (Pubitemid 26047563)
33. M Moroni C Porta M De Amici S Quaglini MA Cattabiani C Buzio 2000 Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients Haematologica 85 298 303 1:CAS:528:DC%2BD3cXjvVamuro%3D 10702820
34. WJ van Driel PC Hogendoorn FW Jansen AH Zwinderman JB Trimbos GJ Fleuren 1996 Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response Hum Pathol 27 904 911 10.1016/S0046- 8177(96)90216-6 8816884 (Pubitemid 26304568)
35. SN Karagiannis MG Bracher J Hunt N McCloskey RL Beavil AJ Beavil DJ Fear RG Thompson N East F Burke RJ Moore DD Dombrowicz FR Balkwill HJ Gould 2007 IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells J Immunol 179 2832 2843 1:CAS:528:DC%2BD2sXpt1Sms78%3D 17709497
36. LM Coussens Z Werb 2001 Inflammatory cells and cancer: think different J Exp Med 193 F23 F26 10.1084/jem.193.6.F23 1:CAS:528:DC%2BD3MXitFKhs7k%3D 11257144
37. GC Cesana F Romano G Piacentini M Scotti A Brenna G Bovo M Vaghi G Aletti R Caprotti H Kaufman F Uggeri 2007 Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis Ann Surg Oncol 14 1295 1304 10.1245/s10434-006-9239-x 17225981 (Pubitemid 46536815)
38. F Donskov KM Bennedsgaard M Hokland N Marcussen R Fisker HH Madsen K Fode H von der Maase 2004 Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma Cancer Immunol Immunother 53 729 739 10.1007/s00262-004-0525-9 1:CAS:528:DC%2BD2cXltF2hsrk%3D 15088127 (Pubitemid 38962067)
39. B Clarke AV Tinker CH Lee S Subramanian M van de Rijn D Turbin S Kalloger G Han K Ceballos MG Cadungog DG Huntsman G Coukos CB Gilks 2008 Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss Mod Pathol 22 393 402 10.1038/modpathol.2008.191 19060844
40. E Sato SH Olson J Ahn B Bundy H Nishikawa F Qian AA Jungbluth D Frosina S Gnjatic C Ambrosone J Kepner T Odunsi G Ritter S Lele YT Chen H Ohtani LJ Old K Odunsi 2005 Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8 +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proc Natl Acad Sci USA 102 18538 18543 10.1073/pnas.0509182102 1:CAS:528:DC%2BD28Xpt1Om 16344461 (Pubitemid 43011261)
41. L Zhang JR Conejo-Garcia D Katsaros PA Gimotty M Massobrio G Regnani A Makrigiannakis H Gray K Schlienger MN Liebman SC Rubin G Coukos 2003 Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 203 213 10.1056/NEJMoa020177 1:CAS:528:DC%2BD3sXksVehug%3D%3D 12529460 (Pubitemid 36077915)
42. O Egeter R Mocikat K Ghoreschi A Dieckmann M Rocken 2000 Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice Cancer Res 60 1515 1520 1:CAS:528:DC%2BD3cXit1aqtrs%3D 10749115
43. NN Hunder H Wallen J Cao DW Hendricks JZ Reilly R Rodmyre A Jungbluth S Gnjatic JA Thompson C Yee 2008 Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1 N Engl J Med 358 2698 2703 10.1056/NEJMoa0800251 1:CAS:528:DC%2BD1cXns1ajtrw%3D 18565862 (Pubitemid 351860862)
44. N Muller-Hermelink H Braumuller B Pichler T Wieder R Mailhammer K Schaak K Ghoreschi A Yazdi R Haubner CA Sander R Mocikat M Schwaiger I Forster R Huss WA Weber M Kneilling M Rocken 2008 TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis Cancer Cell 13 507 518 10.1016/j.ccr.2008.04.001 18538734 (Pubitemid 351763899)
45. JM Grange O Bottasso CA Stanford JL Stanford 2008 The use of mycobacterial adjuvant-based agents for immunotherapy of cancer Vaccine 26 4984 4990 10.1016/j.vaccine.2008.06.092 1:CAS:528:DC%2BD1cXhtVyns7fI 18625281
46. MP Schon M Schon 2008 TLR7 and TLR8 as targets in cancer therapy Oncogene 27 190 199 10.1038/sj.onc.1210913 1:STN:280:DC%2BD1c%2FhtFWjsQ%3D%3D 18176600
47. LM Ellis DJ Hicklin 2008 VEGF-targeted therapy: mechanisms of anti-tumour activity Nat Rev Cancer 8 579 591 10.1038/nrc2403 1:CAS:528: DC%2BD1cXovV2lsro%3D 18596824
48. R Longo G Gasparini 2008 Anti-VEGF therapy: the search for clinical biomarkers Expert Rev Mol Diagn 8 301 314 10.1586/14737159.8.3.301 1:CAS:528:DC%2BD1cXlvFyns7Y%3D 18598109 (Pubitemid 351724709)